Cargando…

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea

AIMS/INTRODUCTION: Glinides are antidiabetic drugs that enhance the early phase of insulin secretion, but have been considered to be less effective at lowering blood glucose than sulfonylureas. However, glinides show a lower risk of hypoglycemia and a greater effect on postprandial hyperglycemia, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omori, Kazuno, Nomoto, Hiroshi, Nakamura, Akinobu, Takase, Takahiro, Cho, Kyu Yong, Ono, Kota, Manda, Naoki, Kurihara, Yoshio, Aoki, Shin, Atsumi, Tatsuya, Miyoshi, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400204/ https://www.ncbi.nlm.nih.gov/pubmed/29963781 http://dx.doi.org/10.1111/jdi.12889

Ejemplares similares

Effect of switching from pioglitazone to the sodium glucose co‐transporter‐2 inhibitor dapagliflozin on body weight and metabolism‐related factors in patients with type 2 diabetes mellitus: An open‐label, prospective, randomized, parallel‐group comparison trial
por: Cho, Kyu Yong, et al.
Publicado: (2018)

Glucose-dependent and Glucose-sensitizing Insulinotropic Effect of Nateglinide: Comparison to Sulfonylureas and Repaglinide
por: Hu, Shiling, et al.
Publicado: (2001)

Repaglinide-Induced Acute Pancreatitis
por: Udongwo, Ndausung, et al.
Publicado: (2021)

Formulation and Evaluation of Transdermal Patch of Repaglinide
por: Prajapati, Shailesh T., et al.
Publicado: (2011)

Favourable effect of the sodium‐glucose co‐transporter‐2 inhibitor canagliflozin plus the dipeptidyl peptidase‐4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open‐label, prospective, randomized, parallel‐group comparison trial (the CALMER study)
por: Cho, Kyu Yong, et al.
Publicado: (2019)

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Takase, Takahiro, et al.
Publicado: (2018)

Development of Spectrofluorimetric and HPLC Methods for In vitro Analysis of Repaglinide
por: Kaushal, N., et al.
Publicado: (2010)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Moses, Robert
Publicado: (2009)

Clinical Effects of Exercise Rehabilitation Combined with Repaglinide in the Treatment of Diabetes
por: Li, Yan, et al.
Publicado: (2022)

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
por: Kitao, Naoyuki, et al.
Publicado: (2017)

Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2012)

Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study
por: Akagi, Yuuki, et al.
Publicado: (2020)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study
por: Kameda, Reina, et al.
Publicado: (2020)

Severe Thrombocytopenia Due to Repaglinide in a Patient With Type 2 Diabetes
por: Katsuyama, Hisayuki, et al.
Publicado: (2013)

Interaction of repaglinide with bovine serum albumin: Spectroscopic and molecular docking approaches
por: Pawar, Suma K., et al.
Publicado: (2019)

The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
por: Guardado-Mendoza, Rodolfo, et al.
Publicado: (2013)

The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy
por: Tanaka, Kenichi, et al.
Publicado: (2017)

Meglitinide (repaglinide) therapy in permanent neonatal diabetes mellitus: two case reports
por: Razzaghy-Azar, Maryam, et al.
Publicado: (2021)

Development of Novel S-Protective Thiolated-Based Mucoadhesive Tablets for Repaglinide: Pharmacokinetic Study
por: Alhakamy, Nabil A., et al.
Publicado: (2022)

Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes
por: Ahmad, Mubashir, et al.
Publicado: (2023)

A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1)
por: Nomoto, Hiroshi, et al.
Publicado: (2016)

Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency
por: Takayama, Kana, et al.
Publicado: (2021)

Comparison of UV spectrophotometry and high performance liquid chromatography methods for the determination of repaglinide in tablets
por: Dhole, Seema M., et al.
Publicado: (2012)

Comparative Study of the Antioxidant Effects of Metformin, Glibenclamide, and Repaglinide in Alloxan-Induced Diabetic Rats
por: Chukwunonso Obi, Bonaventure, et al.
Publicado: (2016)

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus
por: Younas, Amna, et al.
Publicado: (2021)

Effect of combination therapy with repaglinide and metformin hydrochloride on glycemic control in Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2014)

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)
por: Nomoto, Hiroshi, et al.
Publicado: (2015)

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
por: Ma, J., et al.
Publicado: (2014)

Antioxidant properties of repaglinide and its protections against cyclosporine A-induced renal tubular injury
por: Li, Dao, et al.
Publicado: (2016)

Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo
por: Kim, Ji-Min, et al.
Publicado: (2021)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
por: Miya, Aika, et al.
Publicado: (2021)

Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance
por: Schmoelzer, Isabella, et al.
Publicado: (2006)

Updated Review: Improved Glycemic Control with Repaglinide-Metformin in Fixed Combination for Patients with Type 2 Diabetes
por: Richard, John W., et al.
Publicado: (2011)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Moses, Robert G
Publicado: (2010)

Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles
por: Ebrahimi, Hossein Ali, et al.
Publicado: (2015)

Impact of chronic unpredicted mild stress-induced depression on repaglinide fate via glucocorticoid signaling pathway
por: Wei, Hongyan, et al.
Publicado: (2017)

Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells
por: Salcher, Stefan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5lee88jc39ksapd6r4s7ptj0vr